In Vivo Expansion of HLA-B35 Alloreactive T Cells Sharing Homologous T Cell Receptors: Evidence for Maintenance of an Oligoclonally Dominated Allospecificity by Persistent Stimulation with an Autologous MHC/Peptide Complex

By Alexander Steinle, Carsten Reinhardt, Petra Jantzer, and Dolores J. Schendel

From the Institute of Immunology, University of Munich, D-80336 Munich, Germany

Summary

The nature of alloantigens seen by T lymphocytes, in particular the role of peptides in allore cognition, has been studied intensively whereas knowledge about the in vivo emergence, diversity, and the structural basis of specificity of alloreactive T cells is very limited. Here we describe human T cell clones that recognize HLA-B35 alloantigens in a peptide-dependent manner. TCR sequence analysis revealed that several of these allospecific clones utilize homologous TCR: they all express TCRAV2/S3J36C1 and TCRBV4/S1J2/S7C2 chains with highly related CDR3 sequences. Thus peptide-specific alloreactivity is reflected in homologous CDR3 sequences in a manner similar to that described for T cells that recognize nominal peptide/self-MHC complexes. The in vivo frequency of this TCR specificity was studied in unstimulated PBL of the responding cell donor who was not sensitized against HLA-B35. The vast majority (>75%) of the VA2/S3J36 junctional regions obtained from two samples of PBL, isolated at a 9-yr interval, encode CDR3 identical or homologous to those of the functionally characterized HLA-B35 allospecific T cells. These data are most easily explained by a model of alloreactivity in which persistent or recurrent exposure to a foreign peptide/self-MHC complex led to the in vivo expansion and long-term maintenance of specific T cells that show fortuitous crossrecognition of an HLA-B35/peptide complex and dominate the alloreponse against HLA-B35.

T cell recognition is confined to peptide stretches of antigenic proteins that are selected by binding to polymorphic peptide-binding grooves of MHC class I and class II molecules (1-3). Positive and negative selection steps in the thymus prepare T cells for this task (4). Self peptides presented by autologous MHC molecules play an essential role in both selection steps (5). Against this background T cell-mediated alloreactivity remains puzzling since it does not concur with the rules of positive and negative selection: alloreactive T cells respond to MHC molecules for which they have not been positively selected. Likewise they are not negatively selected against self peptides presented by allogeneic molecules (subsequently referred to as “allo-self complexes”), rather they are specifically reactive for such allo-self complexes (6, 7). Characterization of T cell clones specific for foreign peptide presented by self MHC and MHC alloantigens demonstrated that alloreactivity is not a function of a particular population of T cells but is an intrinsic property of many T cells (8, 9) and that this dual specificity is accomplished by one TCR (10). It is assumed that alloreactivity represents fortuitous cross-reactive binding of TCR to particular allo-self complexes but the molecular basis of this cross-reactivity is not yet fully understood (11, 12).

Insight into the structural basis of alloresponses can be gained by analyzing TCR of alloreactive T cells. A three-dimensional model of the TCR proposes that CDR1 and 2, encoded by TCRAV and TCRBV gene segments, interact with the α-helices of the MHC molecules and the hypervariable CDR3, encoded by V-(D)-J junctional regions, contact protruded peptide side chains (13). Analyses of alloreactive T cells in mice and humans revealed a complex TCR usage and support the hypothesis that an alloreponse is mediated by heterogeneous T cells recognizing a wide variety of allo-self complexes (14-17).

In contrast, we show here that a group of HLA-B35 specific, peptide-dependent, alloreactive T cells utilize a set of distinct, yet nearly identical TCR. One of these TCR sequences was found to be predominantly expressed in the unstimulated PBL of the donor whose cells were stimulated in vitro to generate the alloreactive T cells. Furthermore, a second of these TCR sequences was detected with high frequency in a PBL sample obtained from this donor nine years later.
Thus, this example of allore cognition represents a case in which an allo-self complex is recognized presumably due to its similarity to a nominal peptide/self-MHC complex that selectively activated and maintained these T cells in vivo over a very long time.

Materials and Methods

Cells. PBL of healthy Caucasian donors were HLA typed using local and International Histocompatibility Workshop reagents. HLA-B35 variants were characterized by DNA sequencing (18). EBV-transformed lymphoblastoid cell lines (LCL),

was used for the cell-mediated lympholysis assay and their complete HLA types are as follows:

| GM | A2,B8,B40,Cw7,DR2,DR3 |
| DS | A2,A3,B*3501,B37,Cw4,Cw6,DR1,DR2 |
| PR | A1,A3,B*3501,Cw4,DR4,DR13 |
| HF | A1,A3,B*3503,B38,Cw4,DR5,DR1,DR3 |
| TL | A2,A24,B13,B*3508,Cw4,DR3,DR7 |
| GN | A3,A31,B*3508,B55,Cw3,Cw4,DR4 |

The HLA-B*3501 gene was isolated from a genomic library of donor DS. The HLA-A,-B,-C null LCL 721.221 (19) was obtained from the ATCC and transplanted by electroporation with HLA-B*3501 cloned into the pHEBo vector (20). P815-HTR, mastocytoma cells were also transfected with HLA-B*3501 as described elsewhere (21). T2 is a fusion product of the T-LCL CEM and the LCL 721.174 and is MHC hemizygous (22). The residual class I region encodes HLA-A2,-Cw1,-B51; the class II region has a large deletion including the TAP and LMP genes (23). Untransfected T2 cells were kindly provided by Dr. R. Tampe (Max-Planck Institute of Biochemistry, Martinsried, Germany); T2 cells transfected with HLA-B*3501 were kindly provided by Dr. M. Takiguchi (Institute of Medical Science, Tokyo, Japan). The cell lines BM28.7 and BM36.1 were generously provided by Dr. A. Ziegler (Institute of Experimental Oncology and Transplantation, Berlin, Germany); they were derived by mutagenesis from the Burkitt’s lymphoma line BJAB; BM28.7 is MHC hemizygous and carries only the A1, Cw4, B*3501 haplotype of BJAB. BM36.1 carries a deletion in its TAP2 gene and lacks a functional peptide transporter (24).

CTL. An HLA-B35-specific CTL line was made by stimulating B35-negative PBL of donor GM, isolated in 1979, with irradiated B*3501-positive lymphocytes of donor DS for 6 d in MLC. After positive selection of CD8+ lymphocytes using anti-CD8-antibody-coated magnetic beads (Dynal, Hamburg, Germany), cloning was performed by seeding 0.3 cells/well in the presence of rIL-2 (40 U/ml) (Proleukin; Eurocetus, Frankfurt, Germany) and irradiated stimulator cells. The remaining CD8+ lymphocytes were cultivated for several months with irradiated stimulator cells (DS) and rIL-2 (40 U/ml). From this CD8+ line Vc2.3-bearing T cells were positively selected implementing mAb F1 (T Cell Sciences, Cambridge, MA) in combination with goat anti-mouse IgG antibodies coupled to magnetic beads (M450; Dynal).

Cell-mediated Lympholysis Assay. Cytotoxic activity was determined using a standard chromium release assay (25). A percent cytotoxicity was calculated using the formula: % lysis = [(experimental cpm - spontaneous cpm)/ (total cpm - spontaneous cpm)] × 100.

Immunofluorescence Analysis and Antibodies. Indirect immunofluorescence was made using unlabeled hybridoma culture supernatants or ascites (1:1,000) in the first step followed by FITC-conjugated goat anti-mouse Ig antibody (F261; Dakopatts, Copenhagen, Denmark). The following antibodies were used: anti-Bw6 (Biotest, Dreieich, Germany) for assessment of HLA-B35; P1 (T Cell Sciences) for detection of Vc2.3+ T cells; and MPC 11 and UCPC 10 (Sigma Chemical Co., St. Louis, MO) as isotype controls. For two-color immunofluorescence samples were incubated with unlabeled primary antibody, washed twice, and stained with PE-labeled rabbit anti-mouse Ig F(ab)2 (Medac, Hamburg, Germany). Free sites were saturated with excess mouse IgG1 and IgG2a (Coulter, Hialeah, FL). Finally, the cells were incubated with FITC-conjugated anti-CD8 mAb (Immunotech, Marseille, France). Analyses were carried out on a FACScan® instrument (Becton Dickinson, Mountain View, CA) with gates set to include only living cells.

Analysis of TCR Usage and Determination of TCR Sequences. Total cellular RNA was isolated using RNAzol B (CINNA/BIOTECX, Houston, TX). TCR A and TCR B cDNA of the T cell clones was synthesized using the oligonucleotides Core and Cbe (26) and of the PBL the T cell line and the Vc2.3 selected T cells using the oligonucleotides C3x5 (5'CAGTGAAGATCCACACCAT6TCGT 3') and C3x7 (5'TAGAGGAGTTGCACGAGAC 3') with RAV-2 reverse transcriptase (Amersham Buchler GmbH, Braunschweig, Germany). For the T cell clones PCR was performed from cDNA with five sets of TCR A (Vx1-6/7-12/13,24,24/17-22/25-29,32) and four sets of TCR B (Vx1-4, 5,5.2,6/7-12/13,13.2,14-18/19-24) in combination with biotinylated oligonucleotides derived from TCR A (T-Cx1) (27) and TCR B (T-Cx2) (28) gene segments, respectively. Oligonucleotides Vx1 to Vx12 with Vx17 to 21 and Vx1 to Vx20 were synthesized according to published sequences (27, 28) and supplemented with the following oligonucleotides:

| Vx13 | 5' GAGGCAATCTCAGGCTACG 3' |
| Vx14 | 5' CAGTCTCAACCAGAGATGC 3' |
| Vx15 | 5' GATGTTAGCAGAGTCCTTTTC 3' |
| Vx16 | 5' TAGCAGAAGCTACGATCCCTCTCC 3' |
| Vx22 | 5' TAGACAGATCTCCGACCTGT 3' |
| Vx24 | 5' GAGGCGCGAACGACCTTTTC 3' |
| Vx25 | 5' ATGCTGAGCTTCACTAATGTTTA 3' |
| Vx26 | 5' AGCGGAGAAATCCTCACCATATA 3' |
| Vx27 | 5' ACCCCTGCTCTCTCTCTCGAATG 3' |
| Vx28 | 5' CAATAGCCCTCTCTCTCTTGTT 3' |
| Vx29 | 5' AGAGGAAGATGCTGTCACCA 3' |
| Vx32 | 5' TGCAATATCTCCAGTACCAAGCA 3' |
| Vx36 | 5' AGGAGGACCTCGACCTCTC 3' |
| Vx36 | 5' CATCCTCAATCTCCTATGACT 3' |
| Vx36 | 5' GATGCTGAGCTTCACTAATGTTTA 3' |

PCR was performed starting with 2 min at 94°C, then 30 cycles of 30 s at 95°C, 30 s at 56°C and 60 s at 72°C, finishing with 5 min at 72°C. Amplification in a 50-μl volume used 2 μl Taq polymerase (Pharmacia, Freiburg, Germany) and an Omnigene thermocycler (Hybaid, Teddington, UK) under tube control. DNA strands were separated using streptavidin-coupled magnetic parti-

1 Abbreviations used in this paper: LCL, lymphoblastoid cell lines; MFI, mean fluorescence intensity.
cles (M-280; Dynal) and 0.1 M NaOH. Direct sequencing was performed with Sequenase 2.0 (Un. States Biochem. Corp., Cleveland, OH) and [\(^{32}\)P]dATP or using the A.L.F. DNA sequencer (Pharmacia) with the AutoRead sequencing kit (Pharmacia) and fluorescein-labeled primers. The repertoire of the T cell line was analyzed for expression of 30 TCRAV and 24 TCRBV gene families in separate PCR. To obtain semiquantitative estimates of gene usage and to monitor efficiency of amplification, primer pairs encompassing a stretch of the TCRAC and TCRBC gene segments, respectively, were included as internal controls in each reaction (5' C\(\alpha\)-ST/3'C\(\alpha\)-ST for TCRA-PCR and 5' C\(\beta\)-ST/3'C\(\beta\)-ST for TCRB-PCR).

P-5'\(\alpha\)-ST: 5' CTGTGCTAGACATGAGGTCT 3'
P-3'\(\alpha\)-ST: 5' CCTGCCTCTGCCGTGAATGT 3'
P-5'\(\beta\)-ST: 5' AAGCAGAGATCTCCCACAC 3'
P-3'\(\beta\)-ST: 5' GAGGTAAAGCCACAGTTGCT 3'

The PCR protocol was as above except that 35 cycles were performed. Amplification products were separated on a 4% NuSieve 3:1 agarose gel (FMC Corp. BioProducts, Rockland, ME) and photographed (Film Type 55; Polaroid, Cambridge, MA). The TCRAV and TCRBV amplicons of the T cell line were directly sequenced as described above.

Sequencing of TCR Junctional Regions from PBL. The cDNA prepared from unstimulated PBL samples of donor GM was amplified with oligonucleotides Va2.3 and Jc36 to isolate TCRAV23J36 junctional regions and oligonucleotides V\(\beta\)4-Sal and J\(\beta\)2.7 for TCRBV4J27 junctional regions.

Va2.3: 5' TGTTCTAGAGGGAGCCACTGTCG 3'
Jc36: 5' GGGAATTCGGGAATAACGGTGAGTCTC 3'
V\(\beta\)4-Sal: 5' CCGTCGACATATGAGAGTGGATTTGTC 3'
J\(\beta\)2.7: 5' CCGAATTCTTTTTCAGGTCCTCTGTC 3'

Both PCR were optimized for specific amplification via primer se-
lection and application of stringent annealing temperatures. PCR started with 2 min at 94°C, then 35 cycles of 30 s at 95°C, 30 s at 62°C (Va2.3) and 58°C (Vb4), respectively; 60 s at 72°C; finishing with 5 min at 72°C. Amplification in a 50-μl volume used 2 U Taq polymerase. Va2S3J36 amplicons were cloned into pUC18 via XbaI and EcoRI and VB4J2S7 amplicons via SalI and EcoRI restriction sites built into the PCR primers. The cloned junctional regions were sequenced with an A.L.F. DNA sequencer using the fluorescein-labeled reverse primer.

Results

Peptide-dependency of HLA-B35-specific, Alloreactive T Cells. The serological specificity HLA-B35 encompasses at least eight different alleles (29). Previously, we described several B35-specific, alloreactive T cell clones derived from donor GM that exhibited different lysis patterns for target cells expressing molecular subtypes of HLA-B35 (18). An additional T cell clone (clone F) not initially characterized is included here. LCL of B*3501 donors were well recognized by all clones, recognition of LCL of B*3508 donors varied among the clones and none of the clones lysed LCL of a B*3503 donor (18 and data not shown). B*3503 and B*3508 differ from B*3501 by single amino acid substitutions at positions thought to interact with the peptide but not to be accessible to a TCR (18). The differences in allorecognition of cells expressing B35 variants suggested that the T cells were specific for particular B35 allo-self complexes. Recognition of EBV peptides could be excluded since all clones lysed activated T cells of donor DS with equal efficiency (data not shown). All clones also lysed the HLA-A, -B, -C null cell line LCL721.221 after transfection with HLA-B*3501, but not untransfected LCL721.221 cells, nor did they lyse murine P815 cells transfected with HLA-B*3501 (30). These results confirmed that HLA-B*3501 molecules played a direct role in determining the specificity of the T cells; the difference with human versus mouse transfectants expressing HLA-B35 suggested that species variations in endogenous peptides might influence allorecognition.

To substantiate the assumption that these T cells were peptide-dependent we studied their lysis of two different B*3501 positive target cells having defects in the transport of endogenous peptides (Fig. 1). BM36.1 cells are TAP2 mutant derivatives of BM28.7. A-1

A

clone A

T A T T T C T G T G C T
T A T G G A G G A C G G
Av14S1

clone B

T A C T C T G T G T G T G A
T A C G
Av2S3

clone C

T A C T C T G T G T G T G A
T T C C
Av12S1

clone D

T A C T C T G T G T G T G A
T C A A G G
Av2S3

clone E

A G T A C G G G A T G G
S N G W
Av23S1

clone F

C C C T G A G G A C C T A A A A T C A T C T
C C T G A G G A
Av8S1

A.1-CD8

T A C T C T G T G T G T G A
I K
Av2S3

V
T T A
Av5S1

R G P P
G G G A C C T C
Av7S2

G L
G G G C T C
Av12S1

Y F C
T A C T T C T G T G C T
Av32S1

506 In Vivo Expansion of Alloreactive T Cells by an Antigenic Mimic
The endogenous HLA-B*3501 molecules is reduced 10-fold (24 and data not shown). All T cell clones lysed BM28.7 cells at levels similar to B*3501 cells of donor DS; whereas BM36.1 cells were not recognized, except by clone F that showed weak lysis compared to BM28.7 cells. T2 cells have no TAP1 and 2 genes and consequently their peptide transport is heavily impaired (22). The endogenous HLA-A2 molecules of T2 are expressed at 20–25% of wild-type level (31); expression of other HLA-class I molecules, such as endogenous HLA-B51, was barely detected (32). T2 cells transfected with B*3501 DNA bound an anti-Bw6 antibody showing that they expressed B*3501 molecules (T2: negative control [mean fluorescence intensity (MFI) = 127], anti-Bw6 [MFI = 208]; T2-B*3501: negative control [MFI = 190], anti-Bw6 [MFI = 341]). Untransfected T2 cells as well as T2-B*3501 transfec-
tants were poorly recognized by all CTL (Fig. 1).

After several months of culture the CD8+ T cell fraction from which the T cell clones were derived exhibited a pattern of lysis similar to those of clones B, C, and D: it lysed 721.221 cells transfected with HLA-B*3501, recognized B*3501 and B*3508, but not B*3503 cells (not shown), and hardly recognized the B*3501 transporter-defective cell lines (Fig. 1). These data supported the conclusion that the clones as well as this line were B35 specific and peptide dependent.

**TCR Sequences of HLA-B35 Alloreactive T Cells.** The TCRα and TCRβ variable regions of the alloreactive T cell clones were sequenced after PCR amplification using family-specific oligonucleotides (Fig. 2, A and B). Interestingly, clones B and D utilized nearly identical TCR: both had recomb-
tined TCRAV2S3 with TCRAJ36 and TCRBV4S1 with TCRBJ2S7 gene segments. The CDR3 sequences of both TCR chains were also strikingly similar; they were of identical overall length and composed of the same or chemically related amino acids located at the same positions (Fig. 3). The other four T cell clones used different TCRAV and TRAJ gene segments. Clones A and C expressed TCRβ chains encoded from TCRBV7 gene segments that had CDR3β regions of identical length with homologous carboxyterminal halves. Five of the six clones used either TCRBJ2S3 or TCRBJ2S7 gene segments that are closely

| clone | TCRα sequences | TCRβ sequences |
|-------|----------------|----------------|
| clone A | CASSQQ | EWLGQGISDQTQYF |
| clone B | GGVFT | YEQYF |
| clone C | ALPLPGMT | YEQYF |
| clone D | GGI | YEQYF |
| clone E | YQTV | TDTQYF |
| clone F | EILQG | NEKLF |

**Figure 2.** Sequences of the TCR A (A) and TCR B (B) junctional regions of the T cell clones A-F and the five TCRα and TCRβ amplons obtained from the T cell line. Amino acid residues are indicated with the single letter code. Since the germ-line sequences for most of the TCRα and TCRβ gene segments are unknown their borders are inferred by comparison with other published cDNA sequences. The BV7S2 gene segment used by clone D differs from the published sequence BV7S2 (clone PL4.19) by a silent C to T substitution in the codon for the carboxy-terminal cysteine. Nucleotide stretches corresponding to TCRBD1 and TCRBD2 sequences are underlined. Boxed nucleotides indicate a frameshift at the N/J junction leading to an out of frame transcript. These sequence data are available from EMBL/GenBank/DDBJ under accession numbers Z46961 (A) and Z46963 (B).
A. In Vivo Expansion of Alloreactive T Cells by an Antigenic Mimic

TCR Usage and Sequences of the HLA-B35-specific, Alloreactive T Cell Line. We also evaluated the TCR usage of the CD8⁺-positive T cell line that was initiated from the same primary MLC as the clones. Repertoire analysis detected five TCRAV (data not shown) and five TCRBV gene segments (Fig. 2), revealing the oligoclonal composition of the line. Direct sequencing of each amplicon resulted in a single, clearly readable sequence even in the V(D)J junctional region (Fig. 3). Thus the vast majority of sequences comprising each amplicon was derived from a clonal TCR. The T cell line also included TCR composed of VA2S3J36 and VB4S1J2S7 rearrangements like those identified in clones B and D. The CDR3 sequences of each receptor chain exhibited close homology, in terms of length and amino acid composition, to CDR3 of clones B and D (Fig. 3). Therefore it seemed likely that the Va2.3 and Vb3.1 chains were expressed by the same T cell population. To demonstrate this directly we isolated TCR-expressing T cells; therefore "50 cloned VA2S3J36 junctional regions were sequenced from each PBL sample. In the 1979 isolate a single sequence identical to the junctional sequence of clone B was found in the majority of CD8⁺ T cells and in a PBL sample from 1988. Two color immunofluorescence of the PBL samples revealed that 3.4 and 2.0% of the CD8⁺ cells expressed Va2.3 TCRα chains, respectively (Fig. 4, E and F). Frequencies of 2-6% were described for VA2.3/CD8⁺ T cells in PBL of healthy individuals (34). For analysis of the VA2S3J36 TCR repertoire we designed a PCR specific for VA2S3J36 rearranged TCR. Single strand chain polymorphism analysis of the PCR products of the two GM samples showed strong distinct bands whereas those of seven other unrelated individuals gave weak bands or smears, as expected for heterogeneous mixtures of TCR having different CDR3 (data not shown). The strong bands of the GM samples indicated a clonal expansion of VA2S3J36 TCR-expressing T cells; therefore >50 cloned VA2S3J36 junctional regions were sequenced from each PBL sample. In the 1979 isolate a single sequence identical to the junctional sequence of the CD8⁺ line was found in the majority of clones (32 of 55) (Fig. 5). Sequence 2 is identical to that of clone D. No PCR clone was found with the junctional sequence of T cell clone B; however one PCR clone identical in amino acid sequence but differing by five nucleotides in the junctional region was found twice (sequence 3). Four additional sequences encoded identical or highly related CDR3. Since two of them differed from sequence I by only one nucleotide they may represent Taq incorporation error variants. Altogether 41 of 55 junctional sequences (75%) could be grouped into one homology class. In the second PBL sample, 27 of the 50 clones (54%) had related junctional sequences (Fig. 4 D), demonstrating that they coexpressed Vb4 receptor chains.

Further TCRα sequences detected in the unselected line were an out of frame VSSJ52C1 transcript, a V7S2J28 sequence with a CDR3 homologous to VA2S3J36 sequences (i.e., an aliphatic residue, followed by a basic aliphatic residue, followed by three small nonpolar residues), a sequence using V12S1 like clone C, and a V32S1J2C1 sequence (Fig. 2 A). Additional TCRB sequences were defined as V6S2J57C2, V13S1J2S7C2, V16S1J1S1C1, and V24S1J55S1C1 (Fig. 2 B). Three of five TCRB sequences characterized in the T cell line used the J2S7 gene segment which is also present in three T cell clones. The VB16S1 and VB24S1 sequences exhibited a unique, common CDR3 that shared the amino acid sequence "DRG" at the same position exclusively encoded by the TCRαJ1 gene segment. In both cases BD1 was joined to the TCRBV and TCRBJ gene segments without insertion of additional nucleotides, thus representing so-called fetal-type TCR. (33).

In Vivo Expansion of HLA-B35 Alloreactive T Cells. TCR with rearranged VA2S3J36 and VB4S2J2S7 gene segments and highly related CDR3 were found in three of seven HLA-B35-specific, alloreactive T cells and one of these was prevalent in the unselected line. To understand how preferential receptor usage arose following allogeneic stimulation we analyzed the diversity of VA2S3J36 TCR in the 1979 PBL sample of donor GM that was used for establishing the alloreactive T cells and in a PBL sample from 1988. Two color immunofluorescence of the PBL samples revealed that 3.4 and 2.0% of the CD8⁺ cells expressed Va2.3 TCRα chains, respectively (Fig. 4, E and F). Frequencies of 2-6% were described for VA2.3/CD8⁺ T cells in PBL of healthy individuals (34). For analysis of the VA2S3J36 TCR repertoire we designed a PCR specific for VA2S3J36 rearranged TCR. Single strand chain polymorphism analysis of the PCR products of the two GM samples showed strong distinct bands whereas those of seven other unrelated individuals gave weak bands or smears, as expected for heterogeneous mixtures of TCR having different CDR3 (data not shown). The strong bands of the GM samples indicated a clonal expansion of VA2S3J36 TCR-expressing T cells; therefore >50 cloned VA2S3J36 junctional regions were sequenced from each PBL sample. In the 1979 isolate a single sequence identical to the junctional sequence of the CD8⁺ line was found in the majority of clones (32 of 55) (Fig. 5). Sequence 2 is identical to that of clone D. No PCR clone was found with the junctional sequence of T cell clone B; however one PCR clone identical in amino acid sequence but differing by five nucleotides in the junctional region was found twice (sequence 3). Four additional sequences encoded identical or highly related CDR3. Since two of them differed from sequence 1 by only one nucleotide they may represent Taq incorporation error variants. Altogether 41 of 55 junctional sequences (75%) could be grouped into one homology class.

In the second PBL sample, 27 of the 50 clones (54%) had junctional regions identical to clone D (Fig. 5). Sequence 1, which was dominant in the 1979 sample was found six times (12%). Again, the junctional sequence of clone B was not
found but a TCR identical in amino acid but differing in nucleotide sequence (sequence 3) was detected five times (10%). Therefore after nine years the repertoire of VA2S3J36 TCR, was still dominated by a particular homology class that represented 76% (38 of 50 clones) of the junctional sequences.

Junctional sequences not belonging to this homology group (sequences 6–23) were diverse in length and amino acid composition. None was found more than three times or in both PBL samples. 10 started with codon AAC encoding asparagine (but none with AAT that also encodes asparagine) indicating that the AAC codon represented the 3' end of the germline TCKAV2S3 sequence. None of these sequences started with a codon for isoleucine, suggesting that the generation of the homologous sequences did not represent a frequent recombination event but that their dominance in the PBL of GM was due to selection through antigenic stimulation.

Sequencing 50 cloned VB4S1J2S7 junctional regions from each PBL sample supported the results of the VA2S3J36 repertoire analysis. In the 1979 isolate we found the VB4S1J2S7 sequence of the T cell line once (Fig. 2 B); in the 1988 isolate the sequence of clone D was found four times. Both sequences correspond to the clonally expanded VA2S3J36 sequences found at the two time points. The remaining VB4S1J2S7 sequences were neither identical nor homologous to those found in the alloreactive T cells (not shown). TCRBJ2S7 is utilized by 15–20% of all TCRB sequences in peripheral blood (35) whereas TCRAJ36 is rearranged by ~0.7% of TCRA sequences (36). Therefore the peripheral VB4S1J2S7 repertoire probably encompasses at least 10-fold more TCR than the VA2S3J36 repertoire. This could explain why we only found the TCRB sequence corresponding to the expanded T cell clone prevalent at each time and that the TCRB sequences occurred at much lower frequencies than the TCRA sequences. Although several hundred clones would need to be sequenced to obtain an accurate frequency distribution in the VB4J2S7 repertoire, these initial findings are in agreement with the preferential expansion of the same T cells identified via their VA2S3J36 sequences.

Discussion
The currently favored model of alloreactivity suggests that peptides associated with allogeneic MHC molecules play a critical role in dictating specificity (6, 7). Functional evidence
supports the peptide-dependency of the HLA-B35–allospecific T cells studied here: first, 721.221 LCL transfected with B*3501 were well lysed, whereas murine mastocytoma cells (P815-B*3501) were not recognized (30). Secondly, these alloreactive T cells did not recognize two HLA-B*3501–expressing cell lines defective in TAP gene expression which fail to present the broad spectra of peptides found in normal cells. Thirdly, these clones distinguished cells expressing allelic variants of B35 that differ by single amino acid exchanges located at positions thought not to directly interact with the TCR but rather with bound peptide. Particularly the amino acid exchanges, Ser116 to Phe116, in the 3-pleated sheet of B*3501, which are shared by B*3502 and B*3503, distinguish these clones from cells expressing allelic variants of B35 that differ by single amino acid exchanges located at positions thought not to directly interact with the TCR but rather with bound peptide. Particularly the amino acid exchange, Ser116 to Phe116, in the 3-pleated sheet of B*3501, which are shared by B*3502 and B*3503.
drastically impaired allore cognition, probably through its effect on determining the carboxyterminal peptide anchor side chains (18). The sources of endogenous peptides recognized by the alloreactive T cells in the context of HLA-B*3501 remain to be defined. Although they could be derived from viral proteins, several viruses of the Herpes family (EBV, CMV, HHV6, HHV7) that persist in lymphoid cells can be ruled out because they show strong tropism for B or T lymphocytes and are normally harbored by very low numbers of lymphocytes. LCL and PHA-stimulated PBL were lysed at very high levels and purified CD4 or CD8 cells were also found to be well recognized in experiments not shown here.

From mass spectrometry studies thousands of different peptides are known to associate with any MHC molecule (37); this extensive diversity would generate suitable ligands for many TCR and could account for the high frequency of alloreactive T cells. Several functional studies of murine and human alloreponses corroborate this model (6–9, 38–40). Less experimental data exists on TCR usage in alloreponses. Sequences of MHC class II specific, alloreactive T cell clones were found to be heterogeneous in usage of TCR V and J gene segments and in CDR3 sequence motifs and no simple correlation between sequence and allospecificity could be drawn (14–16). One study demonstrated biased usage of TCRBV elements and a nonrandom, but fairly heterogeneous composition of CDR3B sequences for HLA-B27 specific, alloreactive T cells; whereas TCRA chains exhibited no common features (17). This type of heterogeneity is expected if many different allo-self complexes induce allogeneic responses.

Our TCR analysis of B35-allospecific T cell clones revealed a contrasting picture. Although usage of different V and J gene segments was detected in this small set of cells, two of six clones were found to express highly related receptors and a third highly related sequence was found as a dominant population in a long-term B35-allospecific T cell line established from the same primary culture from which the T cell clones were derived. These results revealed that a very restricted TCR usage can dominate an alloreponse. This dominance could be explained either by a strong immunogenicity of the peptide/B35 ligand or by a selective in vivo expansion of these particular T cells. Sequencing of VA2S3J36 transcripts of the PBL sample used for generation of these B35 alloreactive T cells revealed that more than 75% of the transcripts belonged to one homologous TCR family including the TCRA sequences of clone D and the CDR3 of T cell line.

Although this pattern of TCR usage contrasts with reports of other alloreactive T cells, conserved TCR usage was described for a xenogenic response of mice to HLA-Cw3 (41) and for antigen specific T cells. For example, TCR specific for influenza peptides presented by HLA class I molecules exhibited dominant usage of certain TCRAV and TCRBV gene segments and highly homologous CDR3 sequences (42, 43). Strong evidence exists that the CDR3 interact with protruded side chains of the antigenic peptide presented by the MHC molecule (3, 44, 45). Accordingly, only one or two amino acids of the CDR3, are critically involved in the interaction with one of the peptide side chains. The CDR3 of these B35-associated TCR all have an isoleucine followed by a basic, aliphatic residue and an amino acid with a small noncharged side chain; similarly the CDR3B show a stretch of three conserved amino acids with glutamic acid followed by two glycine residues. These particular arrangements in the CDR3 and similar functional patterns support the contention that these TCR recognize the same or highly related peptides and that their specificity can be attributed to CDR3 sequences in a manner analogous to self MHC-restricted T cells. For these alloreactive T cells the specificity of the TCR would appear to result from a direct interaction with a peptide presented by B35 and not from an indirect conformational effect of peptide on the MHC molecule. The role of peptide in driving this selection is best exemplified by the finding that from an in vivo pool of VA2S3J36 and VB4J2S7 TCR with rather different CDR3 only those with homologous CDR3 were found among the B35-alloreactive T cells.

The nature of the original stimulus that led to in vivo expansion of these particular T cells remains unknown: the donor was not directly exposed to a B35-associated allogeneic stimulus through transplantation, blood transfusion, or pregnancy. Even stronger clonal expansions of particular CD8+ T cells that dominate a given Vβ family were described for elderly individuals, but their specificity was not characterized (46). A recent study of Burrows et al. demonstrated that the alloreponse to HLA-B*4402 of HLA-B8, EBV-seropositive individuals is dominated by CTL that recognize an EBNA3-derived peptide presented by HLA-B8; thus a pathogen driven response in vivo can result in a cross-reactive allogeneic response in vitro (47). EBV transformed B cells of donor GM were not recognized by the HLA-B35-alloreactive T cells (data not shown), although EBV would provide a persistent stimulus in vivo.

The maintenance of oligoclonally expanded, alloreactive T cell populations over long periods could have important implications for transplantation. Acute graft rejection occurring from one week to several months after transplantation is usually considered to be initiated by interactions of T helper and CTL; a restricted Vβ usage was shown for alloreactive T cell lines established from renal allografts during an active phase of rejection (48). The immunological basis of accelerated (early acute) graft rejection that occurs within days of engraftment is unclear, although it is also thought to be cell mediated (49). The prevalence of presensitized CTL that mediate alloreponses against a class I mismatched graft may contribute to this practically untreatable form of rejection. If preexpanded T cell populations sharing homologous TCR cause early acute allograft rejection it may be possible to develop strategies to achieve TCR-specific immunosuppression similar to those utilized in experimental animal models (50).
References

1. Rammensee, H.-G., K. Falk, and O. Rötzschke. 1993. Peptides naturally presented by MHC class I molecules. *Ann. Rev. Immunol.* 11:213–244.

2. Barber, L.D., and P. Parham. 1993. Peptide binding to major histocompatibility complex molecules. *Ann. Rev. Cell Biol.* 9:163–206.

3. Jorgensen, J.L., P.A. Reay, E.W. Ehrich, and M.M. Davis. 1992. Molecular components of T-cell recognition. *Ann. Rev. Immunol.* 10:835–873.

4. Von Boehmer, H. 1992. Thymic selection: a matter of life and death. *Immunol. Today.* 13:454–458.

5. Bevan, M.J., K.A. Hogquist, and S.C. Jameson. 1994. Selecting the T cell receptor repertoire. *Immunol. Today.* 13:454–458.

6. Lechler, R., and G. Lombardi. 1991. Structural aspects of allorecognition. *Ann. Rev. Immunol.* 11:385–402.

7. Sherman, L.A., and S. Chattopadhyay. 1993. The molecular basis of allorecognition. *Ann. Rev. Immunol.* 11:385–402.

8. Matis, L.A., S.B. Sorger, D.L. McElligott, P.J. Fink, and S.M. Hedrick. 1987. The molecular basis of allorecognition in antigen-specific, major histocompatibility complex-restricted T cell clones. *Cell.* 51:59–69.

9. Ashwell, J.D., C. Chen, and R.H. Schwartz. 1986. High frequency and nonrandom distribution of alloreactivity in T cell clones selected for recognition of foreign antigen in association with self class II molecules. *J. Immunol.* 136:389–395.

10. Matis, L.A., S.B. Sorger, D.L. McElligott, P.J. Fink, and S.M. Hedrick. 1987. The molecular basis of allorecognition in antigen-specific, major histocompatibility complex-restricted T cell clones. *Cell.* 51:59–69.

11. Sredni, B., and R.H. Schwartz. 1980. Alloreactivity of an antigen-specific T-cell clone. *Nature (Lond.)* 287:855–857.

12. Hünig, T., and M.J. Bevan. 1981. Specificity of T-cell clones illustrates altered self hypothesis. *Nature (Lond.)* 294:460–462.

13. Davis, M.M., and P.J. Bjorkman. 1988. T-cell antigen receptor genes and T-cell recognition. *Nature (Lond.)* 339:495–402.

14. Bill, J., J. Yagüe, V.B. Appel, J. White, H.A. Erlich, and E. Palmer. 1989. Molecular genetic analysis of 178 I-A^k^2^1^2^-reactive T cells. *J. Exp. Med.* 169:115–133.

15. Geiger, M.J., J. Gorski, and D.D. Eckels. 1991. T cell receptor gene segment utilization by HLA-DRK1-alloreactive T cell clones. *J. Immunol.* 147:2082–2087.

16. Obata, F., and N. Kashiwagi. 1992. Sequence analyses of the T-cell receptors utilized for recognition of HLA class II molecules. In *HLA* 1991. K. Tsuji, M. Aizawa, and T. Sasazuki, editors. Oxford University Press, Oxford. 865–901.

17. Lauzurica, P., R. Bragado, D. Lopez, B. Galocha, and J.A. Lopez de Castro. 1992. Asymmetric selection of T cell antigen receptor α- and β-chains in HLA-B27 alloreactivity. *J. Immunol.* 148:3624–3630.

18. Steinle, A., C. Reinhardt, E. Nößner, B. Uchanska-Ziegler, A. Ziegler, and D.J. Schendel. 1993. Microheterogeneity in HLA-B35 alleles influences peptide-dependent allorecognition by cytotoxic T cells but non binding of a peptide-restricted monoclonal antibody. *Hum. Immunol.* 38:261–269.

19. Shimizu, Y., and R. DeMars. 1989. Production of human cells expressing individual transferred HLA-A-, B-, C genes using an HLA-A-, B-, C null human cell line. *J. Immunol.* 142:3320–3328.

20. Sugden, B., K. Marsh, and J. Yates. 1985. A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus. *Mol. Cell Biol.* 5:410–413.

21. Uchanska-Ziegler, B., E. Nößner, A. Schenk, A. Ziegler, and D.J. Schendel. 1993. Soluble T cell receptor-like properties of an HLA-B35-specific monoclonal antibody (TU165). *Eur. J. Immunol.* 23:734–738.

22. Salt, R.D., and P. Cresswell. 1986. Impaired assembly and transport of HLA-A and -B antigens in a mutant TcB cell hybrid. *EMBO (Eur. Mol. Biol. Organ.)* 5:943–949.

23. Spies, T., M. Bresnahan, S. Bahram, D. Arnold, G. Blanck, E. Mellins, D. Pious, and R. DeMars. 1990. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. *Nature (Lond.)* 348:744–747.

24. Kelly, A., S.H. Powis, L.-A. Kerr, I. Mockridge, T. Elliott, J. Bastin, B. Uchanska-Ziegler, A. Ziegler, J. Trowsdale, and A. Townsend. 1992. Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex. *Nature (Lond.)* 355:641–644.

25. Schendel, D.J., R. Wank, and B. Dupont. 1979. Standardization of the human in vitro cell-mediated lympholysis technique. *Tissue Antigens.* 13:112–120.

26. Broeren, C.P.M., G.M.G.M. Verjans, W. Van Eden, J.G. Kusters, J.A. Lenstra, and T. Logtenberg. 1991. Conserved nucleotide sequences at the 5' end of T cell receptor variable genes facilitate polymerase chain reaction amplification. *Eur. J. Immunol.* 21:569–575.

27. Davies, T.F., A. Martin, E.S. Concepcion, P. Graves, L. Cohen, and A. Ben-Nun. 1991. Evidence of limited variability of antigen receptors on intrathyroidal T cells in autoimmune thyroid disease. *N. Engl. J. Med.* 325:238–244.

28. Choi, Y., B. Kotzin, L. Herron, J. Callahan, P. Marrack, and...
37. Hunt, D.F., R.A. Henderson, J. Shabanowitz, K. Sakaguchi.
38. Ritzschke, O., M. Pando, J.M. Delfino, M. Takiguchi, and M.L. Satz. 1993. Isolation and characterization of two new functional subtypes of HLA-B35. *Tissue Antigens.* 41:143-147.
39. Heath, W.R., K.P. Kane, M.F. Mescher, and L.A. Sherman.
40. Crumpacker, D.B., J. Alexander, P. Cresswell, and V.H. Engeldhart. 1992. Role of endogenous peptides in murine allogeneic cytotoxic T cell responses assessed using transfectants of the antigen-processing mutant 174xCEM.T2. *J. Immunol.* 148:3004-3111.
41. MacDonald, H.R., J.-L. Casanova, J.L. Maryanski, and J.-C. Cerottini. 1993. Oligoclonal expansion of major histocompatibility complex class I-restricted cytolytic T lymphocytes during a primary immune response in vivo: direct monitoring by flow cytometry and polymerase chain reaction. *J. Exp. Med.* 177: 1487-1492.
42. Moss, P.A.H., R.J. Moots, W.M.C. Rosenberg, S.J. Rowland-Jones, H.C. Bodmer, A.J. McMichael, and J.I. Bell. 1991. Extensive conservation of \( \alpha \) and \( \beta \) chains of the human T-cell antigen receptor recognizing HLA-A2 and influenza A matrix peptide. *Proc. Natl. Acad. Sci. USA.* 88:8987-8990.
43. Bowness, P., P.A.H. Moss, S. Rowland-Jones, J.I. Bell, and A.J. McMichael. 1993. Conservation of T cell receptor usage by HLA B27-restricted influenza-specific cytotoxic T lymphocytes suggests a general pattern for antigen-specific major histocompatibility complex class I-restricted responses. *Eur. J. Immunol.* 23:1417-1421.
44. Engel, I., and S.M. Hedrick. 1988. Site-directed mutations in the VDJ junctional region of a T cell receptor \( \beta \) chain cause changes in antigenic peptide recognition. *Cell.* 54:473-484.
45. Kelly, J.M., S.J. Sterry, S. Cost, S.J. Turner, J. Fecondo, S. Rodda, P.J. Fink, and F.R. Carbon. 1993. Identification of conserved T cell receptor CDR3 residues contacting known exposed peptide side chains from a major histocompatibility complex class I-bound determinant. *Eur. J. Immunol.* 23: 3318-3326.
46. Posnett, D.N., R. Sinha, S. Kabak, and C. Russo. 1994. Clonal populations of T cells in normal elderly humans: the T cell equivalent to "benign monoclonal gammapathy". *J. Exp. Med.* 179:609-618.
47. Burrows, S.R., R. Khanna, J.M. Burrows, and D.J. Moss. 1994. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. *J. Exp. Med.* 179:1155-1161.
48. Miceli, M.C., and O.J. Finn. 1989. T cell receptor \( \beta \) chain selection in human allograft rejection. *J. Immunol.* 142:81-86.
49. Mason, D.W., and P.J. Morris. 1986. Effector mechanisms in allograft rejection. *Annu. Rev. Immunol.* 4:119-145.
50. Goss, J.A., M.A. Alexander-Miller, J. Gorka, M.W. Flye, J.M. Connolly, and T.H. Hansen. 1993. Specific prolongation of allograft survival by a T-cell receptor derived peptide. *Proc. Natl. Acad. Sci. USA.* 90:9872-9876.